Panasonic teams up with 7X Paralympic Champion Hannah Cockroft for Paris 2024 Paralympic Games
31.8.2023 18:31:00 EEST | Business Wire | Press release
Celebrating the countdown to the Paris 2024 Paralympic Games, Worldwide Olympic and Paralympic Partner Panasonic joins forces with the Team England wheelchair racing 7-time Paralympic Champion and 12-time World Champion, Hannah Cockroft to promote environmental sustainability on a global scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831059501/en/
Hannah Cockroft (Photo: Business Wire)
Since its founding, Panasonic has been committed to making positive contributions to the world and society. It has set ambitious targets to create a positive impact on environmental sustainability under its Panasonic GREEN IMPACT initiative. Hannah will join Team Panasonic as an ambassador focused on sustainability and inclusivity while receiving support from the company on her journey to her fourth Paralympic Games.
After picking up wheelchair racing at a talent day at Loughborough University in October 2007, Hannah has blazed a trail straight to legend status. As one of the most successful para-athletes in recent times, Hannah is looking forward to continuing to inspire people all over the world to embrace the Paralympic movement and celebrate inclusion.
Besides her tremendous athletic achievements, Hannah was one of 50+ Tokyo Olympians and Paralympians from 35 different countries, who took part in the Athletes of the World campaign which challenged World Leaders about the urgent need for ambitious climate action.
She is additionally using her platform to make a difference in issues beyond the sports arena, such as working with federations to reduce the use of single-use plastics. Panasonic is looking forward to working together with her on similar projects and initiatives that epitomise Panasonic’s core values of Contribution to Society, Cooperation & Team Spirit, and Untiring Effort & Improvement.
Hannah Cockroft comments, “It is a privilege to have Panasonic supporting me as I head into the Paris 2024 Paralympic Games. The backing and promotion to a wider audience will help me retain my top performing athlete position and enable me in turn to champion the need for climate change action, and increased inclusivity on a wider scale.”
Panasonic Champions the Champions
Panasonic has supported the Olympic and Paralympic Movements and their Athletes for nearly four decades. Several world-class athletes have been part of its Team Panasonic extended family. These athletes are committed to breaking barriers, improving communities, and bringing awareness to important issues such as sustainability, diversity, and inclusivity, and Hannah is no exception.
Junichi Suzuki, Chairman and CEO of Panasonic Europe B.V. comments, “Hannah’s focus on societal change, including being a patron and ambassador for several charities that enable her to encourage others to get active, alongside her participation in the sustainability initiatives, embodies the spirit of Team Panasonic.
We are proud to welcome her to the Team Panasonic family and have her be part of our team to shine a light on global climate change initiatives and innovations that tackle the world’s most pressing environmental problems.”
For more information about Panasonic GREEN IMPACT vision visit: https://www.panasonic.com/uk/corporate/sustainability.html
For more information about Panasonic as a Worldwide Olympic and Paralympic Partner visit: Panasonic Official Olympic & Paralympic Website| Panasonic Holdings
About the Panasonic Group
Founded in 1918, and today a global leader in developing innovative technologies and solutions for wide-ranging applications in the consumer electronics, housing, automotive, industry, communications, and energy sectors worldwide, the Panasonic Group switched to an operating company system on April 1, 2022 with Panasonic Holdings Corporation serving as a holding company and eight companies positioned under its umbrella. The Group reported consolidated net sales of 8,378.9 billion yen (ca. 59.4 billion Euro) for the year ended March 31, 2023.
To learn more about the Panasonic Group, please visit: https://holdings.panasonic/global/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831059501/en/
Contact information
Tanya Houston, Wildwood Plus, tanya.houston@wildwoodplus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 14:42:00 EEST | Press release
Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429263104/en/ • Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn • Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditions • Transaction expected to close in
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 14:00:00 EEST | Press release
Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S. Marines. The Next Generation EW prototype is centered on the C5ISR Modular Open Suite of S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 14:00:00 EEST | Press release
Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means our partners can choose the networks that best fit their needs, while relying on Visa to provide
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Prior
European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom